Raid Aljumaily

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

Ziming Wang, Ethan G. Aguilar, Jesus I. Luna et al. · Nature Medicine · 2018 · 845 citations

Medicine, Immunology, Oncology +17

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Manish R. Patel, John Ellerton, Jeffrey R. Infante et al. · The Lancet Oncology · 2017 · 588 citations · Full text

Medicine, Oncology, Urology +12

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Tibor Csőszi, Marina Maglakelidze, Robert J. Hoyer et al. · Annals of Oncology · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacology +16

Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)

Suzanne L. Topalian, Shailender Bhatia, Antoine Hollebecque et al. · Cancer Research · 2017 · 149 citations

Medicine, Dermatology, Oncology +17

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Lowell L. Hart, Renata Ferrarotto, Zoran Andrić et al. · Advances in Therapy · 2020 · 125 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15